Edwards Lifesciences (EW) Change in Receivables (2009 - 2026)

Edwards Lifesciences' Change in Receivables history runs 18 years deep, the most recent figure standing at $117.9 million for Q1 2026.

• In Q1 2026, Change in Receivables rose 169.79% year-over-year to $117.9 million; the TTM figure through Mar 2026 stood at $97.2 million (up 173.36% YoY), while the FY2025 annual figure was $23.0 million, up 118.98% from the prior year.
• Change in Receivables was $117.9 million for Q1 2026 at Edwards Lifesciences, up from -$32.4 million in the prior quarter.
• In the past five years, Change in Receivables ranged from a high of $117.9 million in Q1 2026 to a low of -$105.9 million in Q4 2024.
• Historically, Change in Receivables has averaged $14.4 million across 5 years, with a median of $18.2 million in 2023.
• The sharpest annual moves came in 2023 and 2024: Change in Receivables surged 1554.55% in 2023, then slumped 3538.46% in 2024.
• A 5-year view of Change in Receivables shows it stood at $1.1 million in 2022, then jumped by 1554.55% to $18.2 million in 2023, then sank by 681.87% to -$105.9 million in 2024, then soared by 69.41% to -$32.4 million in 2025, then surged by 463.89% to $117.9 million in 2026.
• The last three Change in Receivables figures came in at $117.9 million (Q1 2026), -$32.4 million (Q4 2025), and -$13.2 million (Q3 2025), per Business Quant data.